{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:42:26Z","timestamp":1790790146303,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.cca.2019.10.049","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T11:15:58Z","timestamp":1573557358000},"page":"264-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["HBcrAg, pg RNA and HBsAg dynamically supervise the seroconversion of HBsAg with anti-viral therapy"],"prefix":"10.1016","volume":"501","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4560-8434","authenticated-orcid":false,"given":"Guanghua","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2019.10.049_b0005","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.cca.2019.10.049_b0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"management of chronic hepatitis B virus infection","volume":"57","author":"EASL clinical practice guidelines","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cca.2019.10.049_b0015","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cca.2019.10.049_b0020","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/hep.28025","article-title":"Present and future therapies of hepatitis B:from discovery to cure","volume":"62","author":"Liang","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cca.2019.10.049_b0025","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jhep.2013.10.021","article-title":"Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration","volume":"60","author":"Allweiss","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cca.2019.10.049_b0030","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.cca.2019.10.049_b0035","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-\u03b1 inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.cca.2019.10.049_b0040","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4254\/wjh.v10.i9.603","article-title":"Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA","volume":"10","author":"Liu","year":"2018","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.cca.2019.10.049_b0045","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/JCM.40.2.439-445.2002","article-title":"Sensitive enzyme immunoassay forepatitis B virus core-related antigens and their correlationto vrus load","volume":"40","author":"Kiumra","year":"2002","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.cca.2019.10.049_b0050","article-title":"Hepatitis B virus core and core-related antigen quantitation in Chinese patients with chronic gene type B and C hepatitis B virus infection","volume":"1726\u20131730","author":"Rokuhara","year":"2005","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.cca.2019.10.049_b0055","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2893.2003.00437.x","article-title":"Clinical evaluation of anew enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment","volume":"10","author":"Rokuhara","year":"2003","journal-title":"Viral Hepatol."},{"key":"10.1016\/j.cca.2019.10.049_b0060","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/jvh.12565","article-title":"Baseline HBsAg and HBcrAg titres allow peg-interferon-based \u2018precision medicine\u2019 in HBeAg-negative chronic hepatitis B patients","volume":"23","author":"Martinot-Peignoux","year":"2016","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.cca.2019.10.049_b0065","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/liv.13346","article-title":"Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA","volume":"37","author":"Wong","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.cca.2019.10.049_b0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jmv.21339","article-title":"Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients","volume":"81","author":"Suzuki","year":"2009","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.cca.2019.10.049_b0075","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/hep.29463","article-title":"Hepatitis B virus pregenomic RNA in hepatocellular carcinoma: a nosological and prognostic determinant","volume":"67","author":"Halgand","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cca.2019.10.049_b0080","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiv397","article-title":"Hepatitis B pregenomic RNA is present in Virions in plasma and is associated with response to Peginterferon and Nucleos(t)ide Analogues","volume":"213","author":"Jansen","year":"2016","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.cca.2019.10.049_b0085","article-title":"Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients","volume":"64","author":"Martinot-Peignoux","year":"2016","journal-title":"J. Viral Hepatitis."},{"issue":"4","key":"10.1016\/j.cca.2019.10.049_b0090","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s11684-017-0590-z","article-title":"Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs","volume":"11","author":"Lu","year":"2017","journal-title":"Front Med."},{"key":"10.1016\/j.cca.2019.10.049_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hepr.12108","article-title":"Guidelines for avoiding risks resulting from discontinuation of nucleoside\/nucleotide analogs in patients with chronic hepatitis B","volume":"44","author":"Tanaka","year":"2014","journal-title":"Hepatol. Res."},{"issue":"9454","key":"10.1016\/j.cca.2019.10.049_b0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alpha-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cca.2019.10.049_b0105","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.23327","article-title":"Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Chang","year":"2010","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cca.2019.10.049_b0110","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","author":"Heathcote","year":"2011","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cca.2019.10.049_b0115","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/hep.20240","article-title":"HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects","volume":"39","author":"Yuen","year":"2004","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cca.2019.10.049_b0120","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0168-8278(97)80168-7","article-title":"Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg","volume":"27","author":"Loriot","year":"1997","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.cca.2019.10.049_b0125","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1053\/j.gastro.2008.07.008","article-title":"HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma","volume":"135","author":"Yuen","year":"2008","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cca.2019.10.049_b0130","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/hep.23464","article-title":"Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus","volume":"51","author":"Simonetti","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cca.2019.10.049_b0135","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccdna during the natural history of chronic hepatitis B and decline during adefovir disoproxil therapy","volume":"126","author":"Werlb-Lapostollb","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cca.2019.10.049_b0140","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1128\/JVI.75.1.311-322.2001","article-title":"Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis","volume":"75","author":"Zhu","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.cca.2019.10.049_b0145","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/j.gastro.2010.04.052","article-title":"Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers","volume":"139","author":"Brunetto","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cca.2019.10.049_b0150","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jcv.2013.08.010","article-title":"Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA","volume":"58","author":"Martinot-Peignoux","year":"2013","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.cca.2019.10.049_b0155","article-title":"Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA","volume":"13061","author":"Chen","year":"2019","journal-title":"J. Viral Hepat."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898119321114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898119321114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:51:06Z","timestamp":1757861466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898119321114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":31,"alternative-id":["S0009898119321114"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2019.10.049","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HBcrAg, pg RNA and HBsAg dynamically supervise the seroconversion of HBsAg with anti-viral therapy","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2019.10.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}